IN8bio cuts staff and pipeline to focus on AML cell therapy
IN8bio, formerly Incysus Therapeutics, has instituted cash-saving measures to funnel resources into advancing its acute myeloid leukaemia (AML) allogenic cell…
IN8bio, formerly Incysus Therapeutics, has instituted cash-saving measures to funnel resources into advancing its acute myeloid leukaemia (AML) allogenic cell…
UCLA Health Jonsson Comprehensive Cancer Center is set to initiate a clinical trial of a personalised cancer vaccine aimed at…
Ultimovacs' cancer vaccine UV1 development has suffered another setback as the UV1 vaccine in combination with MSD’s Keytruda (pembrolizumab) failed…
Immorna Biotherapeutics investigational new drug (IND) application for a Phase I/II study of its cancer therapeutic JCXH-211 intravenous (IV) has…
Anti-obesity drugs will be the most impactful trend of 2024, followed by personalised and precision medicine, immuno-oncology (IO) drug development,…
AbbVie has announced positive data for its antibody-drug conjugate (ADC) therapies, Teliso-V, ABBV-400 and ABBV-706, from Phase I and II…
US-based Rakuten Medical has announced positive interim data from the Phase Ib/II trial of its photoimmunotherapy, ASP-1929, in combination with…
Merck & Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from Phase II and…
Last month, the Oncologic Drugs Advisory Committee (ODAC) for the US Food and Drug Administration (FDA) voted in favour of…
Bristol Myers Squibb’s (BMS) blockbuster cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet the primary endpoint as a…